ProPhase Labs Shares Jump 26% on $5.3M ATM Offering and Planned ABL Merger

Introduction

PROPHASE LABS INC (Nasdaq: PRPH) is a biotechnology, genomics, and consumer products company headquartered in Garden City, New York. The firm develops, manufactures, and commercializes health and wellness solutions, including whole genome sequencing services, diagnostics for early cancer detection, and over-the-counter dietary supplements. On December 22, 2025, PRPH closed at $1.13 per share, reflecting a 25.98 percent increase, with a trading volume of 235,950 shares.

Corporate Structure

ProPhase Labs employs between 51 and 200 people across its Garden City headquarters and multiple CLIA-certified laboratories. The company’s leadership includes Chairman and CEO Ted Karkus, who previously scaled ID Biomedical to a $1.4 billion sale, and Jason Karkus, President of Nebula Genomics. Strategic units include:

• Nebula Genomics, providing direct-to-consumer whole genome sequencing;
• ProPhase Diagnostics, operating two CLIA labs with revenues reported at over $200 million since 2021;
• ProPhase BioPharma, focused on cancer diagnostics and therapeutics.

Biotechnology by Louis Reed

Developments and News

On December 19, 2025, ProPhase Labs signed a non-binding letter of intent for a proposed reverse merger with Advanced Biological Laboratories. The same day, the company filed two Form 8-K reports (Acc-no. 0001493152-25-028537 and 0001493152-25-028483) disclosing material corporate events, and submitted a Form 424B5 prospectus (Acc-no. 0001493152-25-028480) to register the sale of up to $5.29 million of common stock at $0.11 per share through an “at-the-market” arrangement with WestPark Capital, Inc.

Financial and Strategic Analysis

As of December 22, 2025, ProPhase Labs’ market capitalization was approximately $41 million, with a 52-week trading range of $0.81 to $9.35. Trailing twelve-month revenue was reported at approximately $5.05 million, while the net loss was $49.56 million, with diluted EPS at –19.80. The balance sheet indicated $0.41 million in cash and a debt-to-equity ratio of 112 percent. The December 19 offering aims to enhance working capital and support research and development in diagnostics and therapeutics. The proposed merger with Advanced Biological Laboratories, if completed, would potentially add biologics manufacturing capacity and diversify the product pipeline.

Market Position and Industry Context

ProPhase Labs operates at the intersection of genomics, diagnostics, and consumer health, competing with established sequencing providers and diagnostic developers. Its multi-channel approach—combining direct-to-consumer genome services, clinician-focused diagnostics, and OTC supplements—aims to create revenue streams. Industry challenges include reimbursement issues for novel diagnostics and the capital intensity of therapeutic development, while opportunities encompass increased demand for early cancer detection and personalized medicine.

tl;dr

ProPhase Labs’ shares increased 25.98 percent to $1.13 on December 22 following the filing of Form 424B5 to raise up to $5.29 million and the signing of a letter of intent on December 19 to merge with Advanced Biological Laboratories. The capital raised and planned reverse merger aim to expand biologics capabilities and support ongoing genomic and diagnostic initiatives.